Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 93 for

Edit search filters
  1. DALY II USA/ MB-CART2019.1 For DLBCL

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A Study To Evaluate Acalabrutinib With Or Without Obinutuzumab To Treat Early-Stage Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma Patients

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Rochester, MN

  5. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study Of Tyrosine Kinase Inhibitor ICP-022 In Patients With R/r B-Cell Malignancies

    Scottsdale/Phoenix, AZ, Rochester, MN

  7. Targeted Therapy Directed By Genetic Testing In Treating Pediatric Patients With Relapsed Or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, Or Histiocytic Disorder

    Rochester, MN

  8. A Study Of CA-4948 In Patients With Relapsed Or Refractory Primary Central Nervous System Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Novel Vaccine (EO2463) As Monotherapy And In Combination, For Treatment Of Patients With Indolent Non-Hodgkin Lymphoma

    Rochester, MN

  10. Low-Dose Selinexor And Choline Salicylate For The Treatment Of Patients With Non-Hodgkin Lymphoma Or Histiocytic/Dendritic Cell Neoplasms

    Rochester, MN

.

Mayo Clinic Footer